CTLA-4 (extra-cellular domain) | MyBioSource MBS395020 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

MyBioSource

product type :

antibody

product name :

CTLA-4 (extra-cellular domain)

catalog :

MBS395020

quantity :

0.1 mg

price :

365 USD

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

AS32

reactivity :

human

application :

neutralization

product information

catalog number :

MBS395020

products type :

Antibody

products full name :

CTLA-4 (extra-cellular domain)

products short name :

CTLA-4 (extra-cellular domain)

products name syn :

CD152; Anti human cytolytic T lymphocyte associated antigen unconjugated; CTLA-4

other names :

cytotoxic T-lymphocyte protein 4 isoform CTLA-4delTM; Cytotoxic T-lymphocyte protein 4; cytotoxic T-lymphocyte protein 4; CD152 isoform; celiac disease 3; cytotoxic T-lymphocyte antigen 4; cytotoxic T-lymphocyte-associated antigen 4; cytotoxic T-lymphocyte-associated serine esterase-4; cytotoxic T lymphocyte associated antigen 4 short spliced form; ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4; cytotoxic T-lymphocyte-associated protein 4; Cytotoxic T-lymphocyte-associated antigen 4

products gene name :

CTLA-4

other gene names :

CTLA4; CTLA4; CD; GSE; GRD4; CD152; CTLA-4; IDDM12; CELIAC3; CD152; CTLA-4

uniprot entry name :

CTLA4_HUMAN

clonality :

Monoclonal

isotype :

IgG1

clone :

AS32

host :

Mouse

reactivity :

Human

sequence length :

174

purity :

Protein A/G Chromatography

form :

Unconjugated

storage stability :

Product should be stored at -20 degree C. Aliquot to avoid freeze/thaw cycles. Stable for 12 months from purchase when stored properly.

tested application :

Neutralization

other info1 :

Immunogen: Recombinant extra-cellular domain of human CD152. Acession Number: P16410,Human

other info2 :

Additional Notes: Neutralization. AS32 has been shown to block interation of soluble hCD152 with hCD80

products categories :

Monoclonal Antibody; Cytokines

products description :

CD152 is one of two ligands (the other CD28) for CD80 and CD86. CD152 acts as co-stimulatory molecule in eliciting T-cell help during antigen presentation.

ncbi gi num :

83700231

ncbi acc num :

NP_001032720.1

ncbi gb acc num :

NM_001037631.2

uniprot acc num :

P16410

ncbi mol weight :

24,656 Da

ncbi pathways :

Adaptive Immune System Pathway (366160); Autoimmune Thyroid Disease Pathway (83121); Autoimmune Thyroid Disease Pathway (533); CTLA4 Inhibitory Signaling Pathway (119556); Calcineurin-regulated NFAT-dependent Transcription In Lymphocytes Pathway (137993); Cell Adhesion Molecules (CAMs) Pathway (83069); Cell Adhesion Molecules (CAMs) Pathway (480); Costimulation By The CD28 Family Pathway (119552); Immune System Pathway (106386); Rheumatoid Arthritis Pathway (200309)

ncbi summary :

This gene is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. Mutations in this gene have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases. [provided by RefSeq, Jul 2008]

uniprot summary :

Function: Inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. Ref.11 Ref.17. Subunit structure: Homodimer; disulfide-linked. Binds to CD80/B7-1 and CD86/B7.2. Ref.21 Ref.22. Subcellular location: Cell membrane; Single-pass type I membrane protein. Note: Exists primarily an intracellular antigen whose surface expression is tightly regulated by restricted trafficking to the cell surface and rapid internalisation;. Ref.18. Tissue specificity: Widely expressed with highest levels in lymphoid tissues. Detected in activated T-cells where expression levels are 30- to 50-fold less than CD28, the stimulatory coreceptor, on the cell surface following activation. Ref.1 Ref.10 Ref.17. Post-translational modification: N-glycosylation is important for dimerization.Phosphorylation at Tyr-201 prevents binding to the AP-2 adapter complex, blocks endocytosis, and leads to retention of CTLA4 on the cell surface. Polymorphism: Genetic variations in CTLA4 are associated with susceptibility to several autoimmune disorders. They influence responsiveness to hepatitis B virus (HBV) infection [. MIM:610424]. Involvement in disease: Systemic lupus erythematosus (SLE) [MIM:152700]: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.Note: Disease susceptibility is associated with variations affecting the gene represented in this entry. Ref.26Genetic variations in CTLA4 may influence susceptibility to Graves disease, an autoimmune disorder associated with overactivity of the thyroid gland and hyperthyroidism. Ref.26Diabetes mellitus, insulin-dependent, 12 (IDDM12) [MIM:601388]: A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical features are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.Note: Disease susceptibility is associated with variations affecting the gene represented in this entry. Ref.23 Ref.26Celiac disease 3 (CELIAC3) [MIM:609755]: A multifactorial, chronic disorder of the small intestine caused by intolerance to gluten. It is characterized by immune-mediated enteropathy associated with failed intestinal absorption, and malnutrition. In predisposed individuals, the ingestion of gluten-containing food such as wheat and rye induces a flat jejunal mucosa with infiltration of lymphocytes.Note: Disease susceptibility is associated with variations affecting the gene represented in this entry. Ref.24 Ref.26 Ref.30. Pharmaceutical use: Engineered fusion proteins consisting of the extracellular domain of CTLA4 and the IgG Fc region (Ctla4-Ig), inhibit T-cell-dependent antibody responses, and are used as immunosuppressive agents. They are soluble, have an enhanced affinity for B7 ligands and act as a competitive inhibitor of CD28. Sequence similarities: Contains 1 Ig-like V-type (immunoglobulin-like) domain.

size1 :

0.1 mg

price1 :

365 USD